Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

PostScription: Experts Everywhere

Author(s):  Rahe Hank

Issue:  Mar/Apr 2005 - Health and Wellness
View All Articles in Issue

Page(s):  167

PostScription: Experts Everywhere Page 1

Download in electronic PDF format for $75

Abstract:  Recent articles by individuals associated with the Controlled Environmental Testing Association (CETA) offer recommendations for barrier isolators used in pharmacy compounding. These recommendations are based, however, on misinterpretations of US Food and Drug Administration (FDA) policy, confusing guidelines for manufacturing with guidelines for compounding. United States Pharmacopeia (USP) Chapter <797> is an enforceable standard for compounding sterile preparations, while FDA regulations govern drug manufacturing processes. Great care has been taken in the construction of USP Chapter <797> to separate the requirements of manufacturing from the pharmacist’s right to compound. Compounding under the definitions and requirements outlined in USP Chapter <797> provide a safe environment without adding the more stringent requirements of the manufacturing environment. Confusing the requirements, as in the CETA documents, not only creates confusion but also endangers the intended separation of manufacturing and compounding.

Related Keywords: Hank Rahe, BSIM, MSE, barrier isolators, cleanroom, United States Pharmacopeia, USP Chapter <797>, US Food and Drug Administration, FDA, airflow, sterile preparation

Related Categories: LEGAL, STERILE PREPARATIONS, UNITED STATES PHARMACOPEIA CONVENTIONS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>,<797>, and <825>: Part 1
Allen Loyd V Jr
Mar/Apr 2020
Pg. 92

PostScription: Experts Everywhere
Rahe Hank
Mar/Apr 2005
Pg. 167

PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>, <797>, and <825>: Part 2
Allen Loyd V Jr
May/Jun 2020
Pg. 180

Basics of Sterile Compounding: Intravenous Admixture Preparation, Part 12: United States Pharmacopeia Chapters Referenced in the Current United States Pharmacopeia Chapter <797> Pharmaceutical Compounding -- Sterile Preparations
Allen Loyd V Jr
Nov/Dec 2021
Pg. 491-496

Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1
Martin Matt
Sep/Oct 2018
Pg. 401-404

A Primer on USP Chapter 797, "Pharmaceutical Compounding - Sterile Preparations," and USP Process for Drug and Practice Standards
Newton David W
, Trissel Lawrence A
Jul/Aug 2004
Pg. 251-263

Update on the Proposed Revision Process for United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations
Okeke Claudia C
Jul/Aug 2007
Pg. 302-305

Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 3: Risk Levels
Allen Loyd V Jr
, Okeke Claudia C
Sep/Oct 2007
Pg. 404-410

United States Pharmacopeia Chapter <797> Timeline: 1989 to 2013
Newton David W
Jul/Aug 2013
Pg. 283-288

Quality Control: Minor Chapters, Major Impacts: What United States Pharmacopeia Chapters <51>, <61>, <62>, and <1207> Mean for Your Compounding Practice
Kelley Brian
Mar/Apr 2021
Pg. 115-124

The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

Technology Spotlight: Barrier Isolators
Moussa Magdy
, Rahe Hank, Lo Katharine
Jan/Feb 2003
Pg. 42-43

Microbial Air-Sampling Equipment, Part 1: Meeting United States Pharmacopeia Chapter <797> Standards
Kastango Eric S
May/Jun 2008
Pg. 216-229

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 6: 2008 Revisions to Chapter <797>
Allen Loyd V Jr
, Okeke Claudia C
Mar/Apr 2008
Pg. 136-144

Proposed Revisions to USP Chapter <797> Pharmaceutical Compounding--Sterile Preparations
Newton David W
Mar/Apr 2005
Pg. 127-130

Misinterpretation of United States Pharmacopeia Chapter <797>
McElhiney Linda F
Jan/Feb 2012
Pg. 6-10

U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

Overview of Chapter <797> "Pharmaceutical Compounding - Sterile Preparations": The Potential Impact for Compounding Pharmacists
Rahe Hank
Mar/Apr 2004
Pg. 89-94

Return to Top